Grace Therapeutics
GRCE
17 hedge funds and large institutions have $3.63M invested in Grace Therapeutics in 2014 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 0 closing their positions.
21% more funds holding
Funds holding: 14 → 17 (+3)
0.18% more ownership
Funds ownership: 4.66% → 4.84% (+0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$61.5K |
| 2 |
Virtu KCG Holdings
New York
|
+$46.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$12.1K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$738 |
Top Sellers
GRCE Hedge Fund Activity: Q4 2014 in Review
17 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2014, worth a combined $3.63M — down 31% from $5.29M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GRCE positions and 0 closed out — a net gain of 4 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Bank of Montreal, adding an estimated $61.5K.
- 17 institutional investors held Grace Therapeutics (GRCE) as of Q4 2014, up from 14 in Q3 2014.
- Funds reported $3.63M of Grace Therapeutics stock for Q4 2014, down 31% quarter-over-quarter.
- 4 funds opened new Grace Therapeutics positions in Q4 2014 and 0 closed out, a net change of +4 holders.
- The largest Grace Therapeutics buyer in Q4 2014 was Bank of Montreal, an estimated $61.5K added.
Based on aggregated 13F filings for Q4 2014.